Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-29 19:14:35 - browse：4392

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： UnitedHealth sued over use of algorithm in Medicare Advantage plans

WSS

Today's health inequities arise from racist U.S. history, say experts

CVS, Rite Aid closures threaten to worsen pharmacy deserts

BD to buy Edwards patient monitoring unit for $4.2 billion

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Medical school prerequisites are outdated

White House drug czar issues call for 'recovery

hotspot

Wikipedia

hotspot

How to save PrEP access — and even expand it

Elevance PBM president out as customers face prescription chaos

Medical leaders decry Supreme Court decision on affirmative action

Take antibiotics after sex, CDC recommends for certain risk groups

Moonlake's readout produced a cash windfall. Risks remain

Finland to offer bird flu vaccine to select groups of people, a possible global first

Cancer drug shortages should be causing more outrage

For pregnant people, addiction treatment shouldn't mean a call to child protective services

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What is STAT's opinion section for?

focus

Congress needs to close a vaccine

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Weight loss drugs should be covered by insurers, AMA says

A letter from the executive editor: STAT UnitedHealth investigation

Carbon Health diabetes program, a test of data

How state and local governments are sidelining science

hotspot

hotspot

explore

explore